Latest Utilities News

ikeGPS Group Limited (IKE) reported a robust FY25 with 19% revenue growth driven by subscription gains and improved margins, setting the stage for EBITDA break-even in FY26 H2 amid strong North American market demand.

ikeGPS Group Limited reported a robust 48% growth in annual subscription revenue exit run rate for FY25, alongside improved margins and a narrowed EBITDA loss. Despite a lucrative NZ$1 per share acquisition approach, the company declined the offer, confident in its growth trajectory.

Atturra Limited is set to acquire DalRae Solutions, a specialist SAP consultancy, in a deal valued up to $20 million that aims to deepen its SAP capabilities and market reach.

Optiscan Imaging Ltd has reached a pivotal milestone with the completion of its cloud-based telepathology software MVP, enabling secure, real-time remote collaboration for digital pathology.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Veris Limited has secured over $2 million in new digital project contracts, reinforcing its leadership in spatial data consulting across energy, transport, and government sectors. These wins highlight the company’s innovative use of proprietary platforms and advanced data capture technologies.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Australis Oil & Gas reported a robust 2024 performance with strong safety and environmental records, maintaining strategic focus on its Tuscaloosa Marine Shale asset despite challenging market conditions.

WestStar Industrial’s subsidiary SIMPEC has landed a $17 million contract to deliver key construction works for a pioneering lithium refining plant in Western Australia, marking a significant step in Australia’s energy transition.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Sayona Mining reports solid FY25 operational gains and outlines strategic merger progress with Piedmont Lithium, positioning itself as a leading North American lithium producer amid a recovering market.

Infinity Lithium Corporation has withdrawn from Spain’s PERTE VEC IIa capital funding program, opting to return nearly €20 million due to prolonged permitting and regulatory hurdles.